Categories Earnings, Health Care

Mylan (MYL) Q3 earnings surpass estimates; revenues miss

Drugmaker Mylan (NASDAQ: MYL) reported third-quarter revenues that fell short of expectations. Meanwhile, earnings increased and surpassed the consensus estimate. The company also revised its full-year 2019 guidance.

Mylan (MYL) Q3 earnings surpass estimates; revenues miss

Revenues increased 3% annually to $2.96 billion, helped by an 8% growth in North America. In Europe sales were almost flat. The top-line missed the estimates. Revenues were negatively impacted unfavorable foreign currency translation, primarily reflecting changes in the U.S. Dollar as compared to the currencies of Mylan’s subsidiaries in the European Union and Australia.

Earnings Beat

Adjusted earnings decreased year-over-year to $1.17 per share during the three month period from $1.25 per share last year, but surpassed the analysts’ forecast. On a reported basis, September-quarter earnings rose to $189.8 million or $0.37 per share from $176.7 million or $0.34 per share last year.

Also see: Pfizer’s stock suffers as Q2 results fail to impress market

“Mylan achieved healthy revenue growth across all segments of our business during the third quarter, supporting solid year-to-date revenue growth as compared with last year on a constant currency basis. Also, this quarter, we continued the purposeful work of transforming our business by applying a highly disciplined financial lens to further maximize the value of our asset base,” said CEO Heather Bresch.

Outlook

The management currently expects full-year 2019 revenues to be in the range of $11.50 billion to $12.00 billion. It continues to expect full-year free cash flow to be between $1.9 billion to $2.3 billion, on an adjusted basis. The earnings forecast has been reaffirmed in the range of $4.20 per share to $4.40 per share.

Also Read:  Teva Pharmaceutical Industries Limited (NYSE: TEVA) Q4 2019 Earnings Call Transcript

Updates

The company said it is making progress towards closing the deal with Pfizer’s Upjohn business by mid-2020, and is on track to launch its biosimilar to Herceptin, Ogivri, later this year.

Related: Mylan Q1 2019 Earnings Conference Call Transcript

Mylan’s stock, which has been on a losing spree since the beginning of the year, closed the last trading session higher.

We’re on Apple News! Follow us to receive the latest stock market, earnings and financial news at your fingertips

Most Popular

BlackBerry (BB) likely to report weak Q4 earnings on March 31

BlackBerry Limited (NYSE: BB) is slated to report its fourth-quarter 2020 earnings results on Tuesday, March 31, after the market closes. The top line will be benefited by BlackBerry Cylance

Companies that are working on the coronavirus vaccine

The coronavirus pandemic continues to plague the world with over 500,000 cases reported globally and over 82,000 cases in the US alone. As the world grapples with the outbreak, several

Altimmune (ALT) reports FY19 results; announces vaccine candidate for COVID-19

Altimmune Inc. (NASDAQ: ALT) reported its earnings results for fiscal-year 2019. Revenues totaled $5.8 million compared to $10.3 million last year. The drop in revenues was caused by lower billings